New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, Ph.D., could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene—a mutation also ...
Jan 9, 2024
0
0
Northwestern Medicine scientists have shed new light on how the deadliest form of thyroid cancer transforms from slow-growing to aggressive, according to research published in the Journal of Clinical Investigation.
May 22, 2023
0
24
Anaplastic thyroid cancer is almost uniformly fatal, with an average lifespan of about 5 months after diagnosis. And standard treatment for the condition includes 7 weeks of radiation, often along with chemotherapy.
May 21, 2018
0
15
(HealthDay)—Two anti-cancer drugs administered together have been approved by the U.S. Food and Drug Administration to treat an inherited form of thyroid cancer.
May 5, 2018
0
5
University of Colorado Cancer Center researchers recently completed the largest-ever study of thyroid cancer genetics, mining the data of 583 patient samples of advanced differentiated thyroid cancer and 196 anaplastic thyroid ...
Apr 26, 2018
0
384
A new treatment combining shock waves with nanoparticles can successfully treat tumours that are difficult to target using conventional chemotherapy. This is the first time this combined therapy has been tested in live animals. ...
May 10, 2017
0
10
(HealthDay)—Two additional quick-reference tools, which offer guidance on management of various thyroid disorders, have been launched by the American Thyroid Association.
Mar 11, 2017
0
0
(HealthDay)—Obesity is associated with increased risk of thyroid cancer, according to a review published online Sept. 14 in Obesity Reviews.
Sep 24, 2015
0
14
Researchers from Memorial Sloan Kettering Cancer Center (MSK) have announced results from the first published basket study, a new form of clinical trial design that explores responses to drugs based on the specific mutations ...
Aug 20, 2015
0
19
In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
Jul 23, 2015
0
8
